From LEADERS to LEADERS FREE : A patient centric approach

With an unrestricted educational grant from Biosensors International

Summary

This video is offered by Biosensors International

Learning Objectives

  • To understand how to identify High Bleeding Risk (HBR) patients and what is the prevalence in clinical practice
  • To learn how LEADERS FREE impacts current management of HBR patients
  • To understand how Bleeding Risk status affects stent choice
  • To explore how Biolimus (BA9) differentiates from other limus drugs and how this may impact clinical outcomes

Presentations available when logged in:

  • Who are High Bleeding Risk patients?
  • High Bleeding Risk patients and 1 month DAPT – A paradigm shift with LEADERS FREE
  • High Bleeding Risk or non-High Bleeding Risk? Insights from clinical practice
  • Are all limus drugs the same? Impact on clinical outcomes with Biolimus (BA9) stent technology